Two decades ago, sequencing the first human genome took over 13 years and cost $3 billion. Today, we can do it in under a day for a few hundred dollars. But here’s the catch: technology has moved forward, healthcare has not.
Two decades ago, sequencing the first human genome took over 13 years and cost $3 billion. Today, we can do it in under a day for a few hundred dollars. But here’s the catch: technology has moved forward, healthcare has not.
While science has advanced rapidly, most systems of care haven’t kept pace with what genomics and AI now make possible. Precision medicine remains aspirational in many places, not because we lack the tools, but because we haven’t reorganized the system around them.
Yet globally, we’re starting to see models that challenge this status quo. In the UAE, 850,000 Emiratis have been sequenced through the Emirati Genome Program. It’s a bold initiative that brings genomics into daily care and public health, not just research labs. Meanwhile, in the UK, where I spent part of my career, the UK Biobank has become one of the world’s most powerful examples of population-scale data driving meaningful discovery. With genomic and clinical data from 500,000 participants, it has enabled landmark studies in everything from cardiovascular disease to mental health. While the UK Biobank remains primarily a research resource, the Emirati Genome Program demonstrates how a national genomics effort can simultaneously advance discovery and deliver direct clinical value — together redefining what implementation at scale can look like. Both models, in very different contexts, are redefining what implementation at scale can look like.
Most people still associate genomics with rare disease diagnostics or oncology, which marked the first wave of its adoption. This next frontier is the integration of genomics with AI and other omics disciplines to build a more complete and dynamic view of human health. By connecting genetic data with molecular, environmental and lifestyle factors, we can start to see biology as a living system that changes and adapts, rather than a fixed code.
This convergence is especially critical in the fight against non-communicable diseases. Conditions like diabetes, cardiovascular disease and metabolic disorders are not driven by rare mutations, but by complex interactions between our stable genetic makeup and environmental pressures. Understanding that interaction, and using it to drive earlier, more precise interventions, is the future of healthcare.
The human genome contains over 3 billion letters. Finding the parts that matter for health is like spotting typos in a library and then realizing they rewrite the ending. AI can now do that in seconds, turning data into diagnosis and guiding prevention with remarkable speed.
But the real bottleneck lies further downstream. Therapeutic development has not kept pace with advances in discovery, and the most promising ideas still falter when moving from discovery to real-world therapies. AI has the potential to change that by modelling biology more accurately, predicting response, and helping design tailored treatments that reach patients faster.
Currently, 90% of clinical trials draw on just 10% of global ethnicities. That’s not only unjust, it’s scientifically flawed. The promise of precision medicine will remain unfulfilled if its evidence base excludes the majority of the world.
Expanding that base requires intentional design. Programs like the UK Biobank and the Emirati Genome Program both demonstrate how population-wide genomics can drive more inclusive, more actionable science. The goal isn’t just faster discovery, it’s smarter, more equitable innovation that reflects the diversity of the people it’s meant to serve.
We are moving toward health systems that continuously learn. Where prevention, diagnosis, treatment and research are coherently connected. The question is no longer whether we can integrate genomics into care, it’s whether we will do so wisely, equitably and at pace.
The science is here. The technology is proven. What’s missing is the urgency. Every year of delay means preventable disease, higher costs and lost lives. Health systems must move from pilots to implementation, from aspiration to action, and from healthcare to health. The real measure of success in this era won’t be sequencing speed or algorithmic power, but the sustainability of systems that keep people well.
By accessing, listening to or reading Beyond Bounds content, you acknowledge and agree that the views expressed by guests and contributors are their own and do not necessarily reflect the views of M42.
All content is provided for general informational purposes only and is not intended as, and should not be relied upon as, medical advice, diagnosis or treatment. Always consult a suitably qualified healthcare professional regarding any medical condition or healthcare decision. Accessing Beyond Bounds content does not create a doctor–patient, clinical, advisory or other professional relationship.
References or links to third-party content, products, services or resources are provided for informational purposes only and do not constitute or imply endorsement by M42. To the fullest extent permitted by applicable law, M42 accepts no liability for any loss, damage or other consequence arising from, or in connection with, access to or reliance upon content in Beyond Bounds.
This disclaimer shall be governed by and construed in accordance with the laws of the United Arab Emirates as applicable in the Emirate of Abu Dhabi. Any dispute arising out of or in connection with this disclaimer shall be subject to the exclusive jurisdiction of the courts of the Emirate of Abu Dhabi.
Subscribe now for best practices, research reports and more
We are bringing together global voices to shape conversations on the future of healthcare, from prevention and precision medicine to AI, sustainability, and health equity.